A 13% undervaluation is a claim in an October 24 headline, not a confirmed market valuation.
The headline says BeOne Medicines could be 13% undervalued as ESMO data improves the outlook. But the information provided includes neither the valuation method nor the underlying ESMO results, so the estimate can’t be independently assessed. BeOne Medicines is listed as BeiGene, Ltd. under ticker ONC.US.
Investor takeaway: The headline ties a 13% undervaluation estimate to ESMO data, but there isn’t enough information here to verify the estimate or assess the clinical findings.
Advertisement
BeiGene, Ltd.
ONC.US
ONC.US
BeiGene, Ltd.
WealthAwesomeMarket cap
$42.19B
P/E
66.3x
52W high
$388.66
52W low
$253.95
1W change
+0.19%
Beta
0.61
Analyst Price Targets
Based on 27 analysts covering ONC · as of Oct 19, 2026
Wall Street analysts forecast ONC stock price to rise 17.7% over the next 12 months.
Consensus
Strong Buy4.67 / 5.00
Avg. Target
C$436.46
+17.7% Upside
Previously C$435.72 on Oct 16, 2026
Current Price
C$370.87
Last close
Analyst Breakdown (27 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ONC's historical volatility
30-Day Vol
31.6%
Annualized
90-Day Vol
29.7%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$443.38
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$393.62 | C$352.90 – C$439.03 |
| 60 trading days | C$417.76 | C$357.98 – C$487.52 |
| 90 trading days | C$443.38 | C$366.97 – C$535.69 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
13% undervalued — according to the October 24 headline
The 13% figure comes from the headline. No valuation model or ESMO results are provided to support it.
Bull case
The headline points to ESMO data as a potential positive. The company’s news list also includes a separate report of sustained survival benefit for a treatment combination.
Bear case
The ESMO results, valuation assumptions, and supporting calculations aren’t provided, so the 13% estimate remains unverified.
What happened: a valuation claim tied to ESMO
An October 24 headline says BeOne Medicines could be 13% undervalued as ESMO data improves the outlook. That’s the claim available here. The information provided doesn’t explain how the estimate was calculated or identify the ESMO findings behind it.
Advertisement
A separate October 24 headline says BeOne presented data on hard-to-treat liver and lung cancers at ESMO 2026, but it doesn’t include study details or results. The company’s news list also includes an October 23 report of sustained survival benefit with a TEVIMBRA-ZIIHERA combination in first-line HER2-positive gastroesophageal cancer. That’s separate news and shouldn’t be treated as evidence for the 13% estimate without more information. See the ONC.US stock page for company and quote details.
What the numbers show: price and trading volume
The latest supplied close for ONC.US was US$356.00. The shares fell 1.79% over one day, rose 0.19% over one week and 2.78% over one month, and gained 19.24% year to date. Latest volume was 41,147 shares, compared with a 20-day average of 352,127 shares. The supplied volume comparison was 0.98x.
The close was US$362.61 relative to the 50-day moving average and US$324.10 relative to the 200-day average. The 52-week range was US$253.95 to US$388.66. These figures describe the share price and trading activity. They don’t verify the valuation estimate or show that ESMO data drove a market reaction. Quote information is also available on the ONC.US stock page.
What to watch next: the missing study and valuation details
The information provided doesn’t identify which ESMO studies the headline refers to, what results they reported, or how those findings might affect the company’s prospects. It also leaves out the assumptions and inputs behind the 13% estimate. Those details are needed to assess the link between the conference data and the valuation claim. Until they’re available, the estimate can be reported, but not confirmed.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
